Ropeginterferon alfa-2b

Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms[1].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Ropeginterferon alfa-2b (5 μg/mL; 72 h) suppresses growth, induces apoptosis and arrests cell cycle at G1 phase in BA-1 cells[1]. Cell Proliferation Assay[1] Cell Line: BA-1 cells Concentration: 5 μg/mL Incubation Time: 72 h Result: Suppressed BA-1 growth. Apoptosis Analysis[1] Cell Line: BA-1 cells Concentration: 5 μg/mL Incubation Time: 24, 48 and 72 h Result: Showed an increase in early- and late-apoptotic cells in a time-dependent manner. Promoted a time-dependent increase in caspase-3 expression. Cell Cycle Analysis[1] Cell Line: BA-1 cells Concentration: 5 μg/mL Incubation Time: 24, 48 and 72 h Result: Induced an increase in G1 phase.

Ropeginterferon alfa-2b (5 μg/mouse; s.c.; single dose) 降低白血病负担，延长白血病小鼠存活时间[1]。 Animal Model: C57BL/6 mice (8-12 weeks) with BA-1 cells[1] Dosage: 5 μg/mouse Administration: Subcutaneous injection, on day 5 after tumor inoculation Result: Led to long-term remission in four of eight (50%) mice.

[1]. Sakatoku K, et al. Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia. Cancer Sci. 2022 Jul;113(7):2246-2257.